{
  "denotations": [
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 143,
        "end": 147
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 170,
        "end": 174
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 170,
        "end": 213
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 248,
        "end": 258
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 283,
        "end": 293
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "27864013_5",
  "text": "METHODS : We did a retrospective individual data analysis based on all published randomised trials that included treatment-naive patients with BRAF ( V600E ) - mutant or BRAF ( V600K ) - mutant metastatic melanoma who received the approved dose of dabrafenib 150 mg twice daily plus trametinib 2 mg once daily ."
}
